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The rapidSTRIPE H1N1 test, based on a nucleic acid lateral-flow assay, has been developed for 
diagnosis of a swine-origin influenza A (H1N1) virus. This test is simple and cost-effective and allows 
specific detection of the S-OIV A (H1N1) virus from swab sampling to final detection on a lateral-flow 
stripe within 2 to 3 h. 
 
In April 2009, a novel swine-origin influenza A (H1N1) virus (S-OIV A) was detected in specimens from 
several patients in the United States and Mexico. This virus spreads from person to person, probably 
in the same way that seasonal influenza viruses spread (16). On 11 June 2009, the World Health 
Organization declared an influenza pandemic caused by novel S-OIV A (H1N1) and raised the 
pandemic alert level to phase 6. Through rapid and frequent international travel, this virus spread 
worldwide, with more than 214 countries and overseas territories or communities reporting laboratory-
confirmed cases of pandemic influenza A H1N1 virus, including at least 18,449 deaths by 6 August 
2010 (17). 
Rapid diagnosis of influenza is important for introduction of antiviral therapy and quarantine measures, 
since antiviral therapy should preferably be initiated within 24 h after appearance of the patient's first 
clinical symptoms (12). This article describes a nucleic acid lateral-flow (NALF) assay, called the 
rapidSTRIPE assay, used as a molecular-genetic rapid test for the diagnosis of the pandemic S-OIV A 
(H1N1) virus. This assay is based on rapid amplification/hybridization (RAH) technology (Analytik Jena 
AG, Jena, Germany). The aim of this study was to evaluate the rapidSTRIPE assay based on a rapid 
amplification/hybridization reaction coupled with instrument-independent detection of the amplification 
products by a user-friendly lateral-flow strip (LFS). Furthermore, the diagnostic sensitivity and 
specificity for the rapidSTRIPE assay were determined and compared to those of the real-time PCR 
method (11), which is widely considered a gold standard (4). 
Two different standard preparations of H1N1 influenza viruses (A/California/04/2009 and 
A/Hamburg/04/2009) were provided by the European Network for Diagnostics of Imported Viral 
Diseases Collaborative Laboratory Response Network (ENVID-CLRN). Different representative 
influenza A and B subtype virus strains for specificity testing were provided by the National Reference 
Center for Influenza, Robert Koch Institute (RKI), Berlin, Germany. Viral RNA samples extracted from 
nasal swabs from patients during the 2009 H1N1 pandemic were kindly provided by the Medizinisches 
Labor Ostsachsen MVZ GbR, Dresden, Germany (MLO MVZ GbR). A total of 174 clinical specimens 
were tested by the rapidSTRIPE H1N1 assay and by reference quantitative real-time PCR. 
The specimens were collected in different patient centers in Saxony, Germany, as pharyngeal or nasal 
swab samples, placed in 200 μl of virus transport medium, and stored at 4°C. The rapidSTRIPE H1N1 
  
assay KF system consists of three modules: module 1 for nucleic acid extraction, module 2 for cDNA 
synthesis and RAH reaction, and module 3 for detection on LFS. Total RNA from swab collection and 
reference virus material was extracted by module 1 of the system using the Innuprep RNA virus 
KFFLX kit (Analytik Jena AG, Jena, Germany) and the Kingfisher FLX system (Thermo Scientific, 
Finland) according to the manufacturer's instructions. In addition, RNA samples from clinical 
specimens included in this study were tested with in-house glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) reverse transcription-PCR (RT-PCR) to check the quality of the extracted 
RNA samples using the AffinityScript One-Step RT-PCR kit (Agilent Technologies, Santa Clara, CA) 
according to the manufacture's instructions. Each RNA was subjected to PCR with the primers 
GAPDHF (5′-CCATGGAGAAGGCTGGGGCT-3′) and GAPDHR (5′-GGTGGTGCAGGAGGCATTGCT-
3′). Subsequently, the amplification products were analyzed by using a 2% ethidium bromide-stained 
agarose gel and were visualized under UV light. 
cDNA synthesis was performed by module 2 of the system with 10 μl of viral RNA in a 15-μl final 
reaction volume according to the manufacturer's instructions. These samples of cDNA were used for 
real-time PCR and the rapidSTRIPE H1N1 assay. Additionally, cDNA synthesis was performed using 
1 μM random hexamer primer for further specificity tests and stored at −80°C until further use. 
Hemagglutinin (HA) gene sequences of S-OIV A (H1N1) virus were aligned by using the ClustalW2 
software program (http://www.ebi.ac.uk/tools/clustalw2/index.html) to design the primers and probe for 
the LFS assay. The RAH reaction was carried out on a cycler or the Alpha SC cycler by using module 
2 of the system according to the manufacturer's instructions. In brief, 3 μl of the cDNA was subjected 
to PCR in a 25-μl-final-volume reaction mixture containing 150 nm of primer HN1 (5′-
TGGGAAATCCAGAGTGTGAATCACTCTC-3′), 300 nm of primer HN2 (5′-Biotin-
CGTTCCATTGTCTGAACTAGRTGTTTCC-3′), and 300 nm of probe HN (5′-fluorescein isothiocyanate 
(FITC)-AGCAAGCTCATGGTCCTACATT-3′). 
Final detection was carried out using module 3 of the system according to the kit instructions. Briefly, 
15 μl of amplification/hybridization product was added to a sample pad on the lateral-flow strip and 
placed in the tube containing 150 μl of running buffer at room temperature. The result was read 
visually after 10 min of incubation. A test was considered positive when the detection line and the 
control line were visible. A test was considered negative when only the control line was visible. 
As a method of comparison, a real-time PCR targeting the HA gene, developed at the Robert Koch 
Institute, was chosen (11). It was performed with 2 μl cDNA in 25-μl reaction volume. Thermal cycling 
was done on a Stratagene Mx3000 cycler instrument (Agilent Technologies, Inc., Santa Clara, CA) 
under the following conditions: 15 min at 95°C, and 45 cycles of 15 s at 95°C and 30 s at 58°C. To 
quantify the real-time PCR, a 10-fold serial dilution of the standard plasmid (10 to 10
6
 copies/μl) was 
tested in duplicate within the same sample run and compared. 
In order to determine the sensitivity of the rapidSTRIPE H1N1 assay KF system, serially diluted 
concentrations of the viral strain A/Hamburg/04/2009 were applied in the LFS assay and in reference 
quantitative real-time PCR after cDNA synthesis. As few as 8 genome equivalent (geq) copies/assay 
of S-OIV A (H1N1) were detected per assay by the reference method, real-time PCR, where as little 
as 84 geq copies/assay of S-OIV A (H1N1) was detected clearly per LFS assay (Fig. 1). In this case, 
the LFS assay showed 10-fold-lower sensitivity than the reference method, real-time PCR. Real-time 
PCR was performed in duplicate, while the LFS assay was performed with a single sample (Fig. 1). 
The same experiments were repeated 3 times independently for the rapidSTRIPE H1N1 assay and 
compared for reproducibility. All three times, as little as 84 geq copies/assay of S-OIV A (H1N1) was 
detected as positive on LFS by the rapidSTRIPE H1N1 assay (data not presented here). 
The specificity of the LFS assay was assessed by testing 10 different strains of subtypes of influenza 
virus A and influenza virus B and human negative-control swab material (Table 1). All tested influenza 
viruses but S-OIV A (H1N1) yielded negative results, demonstrating the high specificity of the LFS 
assay. The reference real-time PCR was also negative for all reference influenza A and influenza B 
virus strains except two strains of influenza A virus (Table 1). Both of the influenza A viruses were 
detected at the threshold of detection, with threshold cycle (CT) values of 38.01 and 38.8, respectively. 
To control the quality of the cDNA of reference influenza viruses, in-house real-time PCR assays for 
influenza A and B viruses (flu A+B) (Analytik Jena AG, Jena, Germany) were performed with all 
  
samples. All of the influenza viruses were positive in the real-time PCR flu A+B assay. Swabs from the 
human negative control and swab control were negative in all three assays. 
One hundred seventy-four viral RNA samples obtained from patient nasal swabs included in this study 
were positive by in-house GAPDH RT-PCR. The same RNA samples were also tested with the 
rapidSTRIPE H1N1 assay and real-time PCR. The CT values obtained by real-time PCR for positive 
samples ranged from 22.58 to 38.9 (data not shown here). One hundred five samples out of 174 
samples (60.3%) were positive and 69 (39.7%) were negative by real-time PCR. Of the 105 samples 
that were detected as positive by real-time PCR, 92 tested positive by the rapidSTRIPE H1N1 assay, 
providing a sensitivity of 88% (95% confidence interval [CI], 80% to 92.6%) and a positive predictive 
value of 96%. Of the 69 samples that tested negative in real-time PCR, 65 tested negative by the 
rapidSTRIPE H1N1 assay, providing a specificity of 94% (95% CI, 86% to 97.7%) and a negative 
predicative value of 84%. The overall agreement between the two assays was 90.2% (157/174). 
Our finding demonstrates the usefulness of the rapidSTRIPE H1N1 assay for the rapid detection of 
novel S-OIV H1N1 as an alternative to real-time PCR in a resource-poor laboratory setting. This assay 
showed no cross-reactivity either with other influenza A and B viruses or with human negative-control 
material, providing a good specificity profile, required for diagnostic accuracy. As little as 84 geq 
copies/assay could be detected by the rapidSTRIPE H1N1 assay, corresponding to 8,400 viral RNA 
copies in 100 μl RNA or 8,400 virus particles in the initial sample (experimental swab sample). The 
rapidSTRIPE test showed an overall sensitivity of 88% and specificity of 94% in comparison to real-
time PCR, the widely preferred method for diagnosis of S-OIV A (H1N1) (4). The total cost of the 
rapidSTRIPE H1N1 test, including manual nucleic acid extraction, is about 10 euros per sample. 
Several PCR-based assays for the detection of the S-OIV A (H1N1) were developed and published 
soon after the emergence of the pandemic 2009 H1N1 virus (1, 9, 10, 14, 15). Also, new rapid assays, 
such as real-time nucleic acid sequence-based amplification and multifluorescent real-time RT-PCR, 
have been developed to detect novel S-OIV A (H1N1) (2, 6). All of these molecular detection methods 
in the form of real-time RT-PCR have been broadly used in medical diagnostic laboratories because of 
their high sensitivities and specificities. Although real-time RT-PCR is widely regarded as a gold 
standard for diagnosis of influenza viruses (4), it is relatively expensive and requires trained laboratory 
expertise and extensive evaluation, which limits the broad use of in-house assays (13). Rapid antigen-
antibody-based influenza tests as point-of-care tests have been used since they require only 10 to 15 
min and minimal expertise for testing. They also provide a source of data for clinical management of 
the patients. However, a high virus concentration is required to yield a positive rapid test (3). 
Depending on the virus load of the respiratory sample, an overall sensitivity of 40% to 69% has been 
reported for rapid antigen-antibody-based influenza tests among different commercial tests (5, 7, 8). 
In summary, the rapidSTRIPE H1N1 assay offers a powerful tool for specific detection of S-OIV A 
(H1N1) in about 2 to 3 h, from swab sampling, nucleic acid isolation, cDNA synthesis, and rapid 
amplification/hybridization to final detection of the PCR products on an LFS. Furthermore, the 
rapidSTRIPE H1N1 assay KF system provides all reagents needed for molecular diagnostics, from 
nucleic acid isolation to final detection on LFS, in one single system. This rapid assay allows 
qualitative detection of S-OIV A (H1N1) with several advantages, such as quickness, cost-
effectiveness, and long-term stability. Readout of the test is performed optically, which makes it 
independent from an instrument-specific analysis system. This system can easily be used as a high-
throughput screening system for laboratories not equipped with real-time PCR instruments and in 
resource-poor diagnostic settings during an epidemic. 
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Tables and Figures 
 
 
Table 1. Specificity test with two reference real-time PCR assays and the rapidSTRIPE test with 
representative influenza virus subtypes. 
 
a
Samples were analyzed in duplicate in the real-time PCR assay and flu A+B assay. CT, threshold 
cycle. 
b
Samples were analyzed once in the LFS assay. 
  
Figure 1. Sensitivity of LFS assay. Serial dilutions of the viral strain A/Hamburg/04/2009 were used to 
evaluate the sensitivity of the LFA assay and compare it with the reference method, RT-quantitative 
PCR (qPCR). Test strip control lines were visible for all samples. Detection lines were visible below 
the test line for the first four dilutions of viral samples. 
 
 
 
 
 
 
 
